Guangzhou Kingmed Diagnostics Group Co Ltd
603882
Company Profile
Business description
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
Contact
International Biological Island spiral three on the 10th
Guangdong Province
Guangzhou510000
CHNT: +86 2022283222
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
10,413
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.80 | 74.40 | 0.84% |
| CAC 40 | 7,817.33 | 95.24 | 1.23% |
| DAX 40 | 24,267.71 | 258.33 | 1.08% |
| Dow JONES (US) | 44,386.34 | 131.56 | 0.30% |
| FTSE 100 | 8,970.64 | 44.09 | 0.49% |
| HKSE | 24,498.95 | 18.81 | -0.08% |
| NASDAQ | 20,755.84 | 25.35 | 0.12% |
| Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
| NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
| S&P 500 | 6,268.56 | 4.86 | 0.08% |
| S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
| SSE Composite Index | 3,516.83 | 13.05 | 0.37% |